John Overdeck’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-49,997
| Closed | -$5.34M | – | 4459 |
|
|
2025
Q3 | $5.34M | Sell |
49,997
-300,545
| -86% | -$31.4M | 0.01% | 1408 |
|
|
2025
Q2 | $33.2M | Buy |
350,542
+271,331
| +343% | +$20.1M | 0.06% | 388 |
|
|
2025
Q1 | $5.03M | Sell |
79,211
-72,893
| -48% | -$4.36M | 0.01% | 1127 |
|
|
2024
Q4 | $7.06M | Buy |
152,104
+82,166
| +117% | +$3.08M | 0.02% | 915 |
|
|
2024
Q3 | $2.01M | Buy |
69,938
+54,141
| +343% | +$1.33M | ﹤0.01% | 1676 |
|
|
2024
Q2 | $228K | Sell |
15,797
-126,017
| -89% | -$1.84M | ﹤0.01% | 2693 |
|
|
2024
Q1 | $2.28M | Buy |
141,814
+94,577
| +200% | +$1.64M | 0.01% | 1390 |
|
|
2023
Q4 | $939K | Buy |
47,237
+10,377
| +28% | +$153K | ﹤0.01% | 2118 |
|
|
2023
Q3 | $601K | Sell |
36,860
-333,815
| -90% | -$6.43M | ﹤0.01% | 2199 |
|
|
2023
Q2 | $7.84M | Sell |
370,675
-34,306
| -8% | -$732K | 0.02% | 739 |
|
|
2023
Q1 | $8.13M | Sell |
404,981
-119,550
| -23% | -$2.58M | 0.02% | 671 |
|
|
2022
Q4 | $13.7M | Buy |
524,531
+163,981
| +45% | +$2.18M | 0.04% | 456 |
|
|
2022
Q3 | $3.69M | Buy |
+360,550
| New | +$3.04M | 0.01% | 871 |
|
Other funds holding VRNA
John Overdeck's VRNA Position: Q4 2025 in Review
John Overdeck sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 49,997 shares — an estimated $5.34M sold.
John Overdeck first reported a position in VRNA in Q3 2022 and held it in 13 quarters. The position peaked at $33.2M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- John Overdeck reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- John Overdeck sold 49,997 Verona Pharma shares in Q4 2025, an estimated $5.34M.
- John Overdeck first reported a position in Verona Pharma in Q3 2022 and held it in 13 quarters.
- John Overdeck's Verona Pharma position peaked at $33.2M in Q2 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Two Sigma Investments's 13F filing for Q4 2025, filed 17 Feb 2026.